MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
-0.040
-2.67%
Closed 19:31 07/08 EDT
OPEN
1.510
PREV CLOSE
1.500
HIGH
1.510
LOW
1.390
VOLUME
167.65K
TURNOVER
--
52 WEEK HIGH
24.45
52 WEEK LOW
0.5552
MARKET CAP
21.75M
P/E (TTM)
-0.9711
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SLRX stock price target is 4.433 with a high estimate of 5.00 and a low estimate of 3.800.

EPS

SLRX News

More
Benchmark Initiates Coverage On Salarius Pharmaceuticals with Speculative Buy Rating, Announces Price Target of $5
Benchmark analyst Aydin Huseynov initiates coverage on Salarius Pharmaceuticals (NASDAQ:SLRX) with a Speculative Buy rating and announces Price Target of $5.
Benzinga · 06/16 11:16
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
Benzinga · 06/14 14:20
MGI, WWR, NNA and ADRO among midday movers
Seeking Alpha - Article · 06/02 16:46
Salarius Pharma Shares Resume Trade Following Circuit Breaker Halt, Stock Continuing Higher, Now Up 48% For Session
Benzinga · 06/02 16:36
Salarius Pharma Shares Spike ~30% As Traders Circulate FDA.gov AdCom Meeting Alert For Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee On Jun. 17-18, 2020
https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-agenda-and-public-participation-information-june-17-18-2020-meeting-pediatric-oncology
Benzinga · 06/02 16:33
Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administrations Oncologic Drugs Advisory Committee
GlobeNewswire · 06/02 14:00
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22
Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program
GlobeNewswire · 05/27 13:00

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About SLRX

Salarius Pharmaceuticals, Inc., formerly Flex Pharma, Inc., is a clinical-stage oncology company. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The Company’s lead candidate, Seclidemstat, is a reversible lysine specific histone demethylase 1 (LSD1) inhibitor. Seclidemstat is in phase I clinical study for treating Ewing sarcoma. Seclidemstat inhibits LSD1's demethylation and scaffolding properties, representing a therapeutic option for patients who need it. The Company is also developing Seclidemstat for a number of cancers with unmet need, with a clinical study in solid tumors including, prostate, breast and ovarian cancers.
More

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.